Summary & Overview
HCPCS Level II J9269: Injection, Tagraxofusp-erzs, 10 Micrograms
HCPCS Level II code J9269 denotes the injection formulation of tagraxofusp-erzs measured in 10 microgram units. Tagraxofusp-erzs is a targeted oncology biologic used in specialist cancer care; its billing code matters nationally because high-cost specialty injectables drive drug spend, site-of-care decisions, and payer coverage policy. This code is relevant for hospital outpatient departments and physician offices that deliver infusion services.
Key payers in this coverage analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9269 represents, the clinical and service settings where it is billed, and the payer landscape under which reimbursement and coverage determinations occur. The publication outlines benchmarks and policy considerations relevant to specialty oncology injectables, describes typical billing contexts for J9269, and summarizes what to expect in payer coverage assessments and claim adjudication patterns.
This national-focused summary provides the clinical context for billing, highlights the parties involved in coverage decisions, and points to the operational settings where J9269 is most frequently used. Data not available in the input for specific taxonomies, diagnosis pairings, or related codes.
Billing Code Overview
HCPCS Level II code J9269 describes injection, tagraxofusp-erzs, 10 micrograms. This code represents a parenteral oncology therapeutic agent supplied and administered in measured microgram doses. The service type is drug administration for a targeted cancer therapy. The typical site of service is hospital outpatient infusion center or physician office infusion suite, where specialty oncology drugs are prepared and delivered under clinical supervision.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who presents for scheduled systemic therapy with tagraxofusp-erzs (manufacturer dose expressed as 10 micrograms per billing unit J9269). The patient is evaluated in an outpatient oncology infusion center or hospital outpatient infusion clinic with baseline vital signs, laboratory review (including liver function tests, albumin, and complete blood count), and assessment for capillary leak syndrome risk. The clinical workflow includes nurse triage, verification of treatment orders and consent, pharmacy preparation of the intravenous formulation, bedside administration via peripheral IV or implanted central venous access device, continuous monitoring during infusion for infusion-related reactions and capillary leak, and post-infusion observation prior to discharge. Typical services documented include drug administration, infusion supervision, infusion-related nursing care, and any supportive medications or interventions used during or after the infusion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard service | Use when no modifier applies and the service is provided as billed. |